Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | MMP2 | P08253 | 1/20 | 0.57 |
| ▸ | MMP9 | P14780 | 1/20 | 0.57 |
| ▸ | PGR | P06401 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | CCR2 | P41597 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1471525 | 0.90 | MEN1 (0.62) | KMT2AMAPTPTGDR2 | |
| SCHEMBL2176669 | 0.83 | LMNA (0.61) | ALDH1A1POLBKMT2AL3MBTL1MAPT | |
| SCHEMBL12407078 | 0.82 | FFAR4 (0.55) | POLBKMT2AMAPTLMNAKDM4E | |
| SCHEMBL12751015 | 0.81 | MAPT (0.45) | POLBMAPTLMNATP53 | |
| SCHEMBL1471568 | 0.81 | MAPT (0.71) | MAPT | |
| SCHEMBL1472284 | 0.81 | MAPT (0.56) | PTGES2ALDH1A1POLBKMT2AL3MBTL1 | |
| SCHEMBL2175966 | 0.80 | TSHR (0.72) | ALDH1A1POLBKMT2AMAPTLMNA | |
| SCHEMBL12407072 | 0.78 | MAPT (0.54) | ALDH1A1POLBKMT2AL3MBTL1MAPT | |
| SCHEMBL29561208 | 0.78 | MAPT (0.57) | MAPTLMNAPTGDR2TP53 | |
| SCHEMBL2174600 | 0.77 | FFAR4 (0.61) | ALDH1A1POLBKMT2AMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7915293-B2 | Carbocyclic and heterocyclic sulfonamide derivatives, e.g., N-(2-bromo-5-(trifluoromethoxy)phenyl)-3,5-dichloro-4-(2-chloro-4-nitrophenoxy)benzenesulfonamide and 4-(2-(trifluoromethyl)phenoxy)-1-(3-trifluoromethyl)phenylsulfonyl)piperidine; treating proliferative diseases | RIGEL PHARMACEUTICALS, INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-7915293-B2 | Carbocyclic and heterocyclic sulfonamide derivatives, e.g., N-(2-bromo-5-(trifluoromethoxy)phenyl)-3,5-dichloro-4-(2-chloro-4-nitrophenoxy)benzenesulfonamide and 4-(2-(trifluoromethyl)phenoxy)-1-(3-trifluoromethyl)phenylsulfonyl)piperidine; treating proliferative diseases | RIGEL PHARMACEUTICALS, INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-7915293-B2 | Carbocyclic and heterocyclic sulfonamide derivatives, e.g., N-(2-bromo-5-(trifluoromethoxy)phenyl)-3,5-dichloro-4-(2-chloro-4-nitrophenoxy)benzenesulfonamide and 4-(2-(trifluoromethyl)phenoxy)-1-(3-trifluoromethyl)phenylsulfonyl)piperidine; treating proliferative diseases | RIGEL PHARMACEUTICALS, INC. (US) | 2011-03-29 | — | — | US | disclosed |
| WO-2005007621-A2 | UBIQUITIN LIGASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2005-01-27 | — | — | WO | disclosed |
| US-20050009871-A1 | Ubiquitin ligase inhibitors | RIGEL PHARMACEUTICALS, INC. | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009871-A1 | Ubiquitin ligase inhibitors | NEDD4, STUB1, UBE3A | PTGES2 3207/4885ALDH1A1 1362/4885POLB 1812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.